Clinical trials: Recurrent Hepatocellular Carcinoma
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
This phase II trial is studying how well MK2206 works in treating patients with advanced liver cancer that did not respond to previous therapy.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma
- Trial name
- NCT01239355
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 22 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer, Metastatic Cancer
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor.
- Trial name
- NCT00003907
- Testing
- cisplatin, doxorubicin, mitomycin
- Where
- 37 sites in United States
- Volunteers
- 50 people
- Sponsor
- Eastern Cooperative Oncology Group
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
This phase II trial is studying how well AZD2171 works in treating patients with locally advanced unresectable or metastatic liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00427973
- Testing
- cediranib maleate, laboratory biomarker analysis, computed tomography
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
This phase II trial is studying how well dasatinib works in treating patients with advanced liver cancer that cannot be removed by surgery.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00459108
- Testing
- dasatinib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Non-Small Cell Lung Cancer Recurrent
A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma
The main purpose of this study is to evaluate the safety, tolerability, and efficacy of the study drug known as galunisertib in combination with nivolumab in participants with advanced refractory solid tumors and in recurrent or…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer Recurrent, Hepatocellular Carcinoma Recurrent
- Trial name
- NCT02423343
- Testing
- Galunisertib, Nivolumab
- Where
- 9 sites in United States, Spain
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Hepatocellular
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are…
- Trial name
- IMbrave050 (NCT04102098)
- Testing
- Atezolizumab, Bevacizumab
- Where
- 134 sites in United States, Australia and 24 more
- Volunteers
- 668 people
- Sponsor
- Hoffmann-La Roche
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
This phase II trial is studying how well giving doxorubicin together with bortezomib works in treating patients with liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00083226
- Testing
- doxorubicin, bortezomib
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00881751
- Testing
- bevacizumab, erlotinib hydrochloride, sorafenib tosylate
- Where
- 6 sites in United States
- Volunteers
- 95 people
- Sponsor
- Medical University of South Carolina
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
IMC-A12 in Treating Patients With Advanced Liver Cancer
This phase II trial is studying how well IMC-A12 works in treating patients with advanced liver cancer. Monoclonal antibodies, such as IMC-A12, can block tumor growth in different ways.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00639509
- Testing
- cixutumumab, computed tomography, contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Adult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
This phase II trial is to see if bevacizumab works in treating patients who have unresectable nonmetastatic liver cancer that has not spread to the main portal vein.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00055692
- Testing
- bevacizumab
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
This pilot clinical trial studies 6,8-bis(benzylthio)octanoic acid in treating patients with advanced or metastatic cholangiocarcinoma that cannot be removed by surgery.
- Conditions
- Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder
- Trial name
- NCT01766219
- Testing
- 6,8-bis(benzylthio)octanoic acid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
This phase II trial is studying how well MD2206 works in treating patients with advanced refractory biliary cancer that cannot be removed by surgery.
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Gallbladder Carcinoma
- Trial name
- NCT01425879
- Testing
- Akt Inhibitor MK2206, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer
Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NRR (NCT00483405)
- Testing
- cetuximab, capecitabine, oxaliplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hepatic Carcinoma
Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy
To evaluate the efficacy and safety of Huaier Granule for prevention of recurrence and metastasis of hepatocarcinoma after radical hepatectomy.
- Trial name
- NCT01770431
- Testing
- Huaier Granule
- Where
- China
- Volunteers
- 1,044 people
- Sponsor
- Qidong Gaitianli Medicines Co., Ltd
Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed.
- Conditions
- Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT02867592
- Testing
- Cabozantinib, Cabozantinib S-malate, Pharmacological Study
- Where
- 142 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Cancer Institute (NCI)
AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have…
- Conditions
- AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma
- Trial name
- NCT02595866
- Testing
- Antiretroviral Therapy, Biopsy, Biospecimen Collection
- Where
- 12 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Liver Cancer
Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, cisplatin, and mitomycin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing.
- Trial name
- NCT00049322
- Testing
- bevacizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Child-Pugh Class A, Child-Pugh Class B
Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization
This randomized phase III trial studies how well transarterial chemoembolization (TACE) works compared to stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy (SABR) in patients with liver cancer…
- Conditions
- Child-Pugh Class A, Child-Pugh Class B, Recurrent Hepatocellular Carcinoma
- Trial name
- NCT02762266
- Testing
- Stereotactic Body Radiation Therapy, Transarterial Chemoembolization, embolic agent
- Where
- 2 sites in United States, Japan
- Volunteers
- 13 people
- Sponsor
- Stanford University
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
This phase I/II trial is studying the side effects and best dose of belinostat and to see how well it works in treating patients with liver cancer that cannot be removed by surgery.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00321594
- Testing
- belinostat
- Where
- 2 sites in United States, Singapore
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
This phase II trial investigates the effect of combining two immune therapies, atezolizumab and CDX-1127 (varlilumab), with or without cobimetinib, in treating patients with biliary tract cancer that cannot be removed by surgery…
- Conditions
- Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma
- Trial name
- NCT04941287
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 29 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)